Clinical trial

Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes

NCT03269058

Study summary

ClinicalTrials.gov

Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Dapagliflozin Normalized identity: dapagliflozin View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebos Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-12-20

PhasePHASE4

Conditions

Type-2 Diabetesunresolved

Oral Antidiabeticsunresolved

Interventions

DapagliflozinDRUG · verified · RxNorm: dapagliflozin

PlacebosDRUG

Sponsors & collaborators

Centre Hospitalier Universitaire Dijonlead sponsor

Mapped research locations

DijonFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03269058 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.